Intelligent Bio Solutions has completed an interference study to validate the accuracy of its drug screening system under real-world conditions, solidifying plans to submit the FDA 510(k) package in the second half of 2026 to enter the U.S. market.
Intelligent Bio Solutions has completed an interference study to validate the accuracy of its drug screening system under real-world conditions, solidifying plans to submit the FDA 510(k) package in the second half of 2026 to enter the U.S. market.